JP2020537649A5 - - Google Patents

Download PDF

Info

Publication number
JP2020537649A5
JP2020537649A5 JP2020520804A JP2020520804A JP2020537649A5 JP 2020537649 A5 JP2020537649 A5 JP 2020537649A5 JP 2020520804 A JP2020520804 A JP 2020520804A JP 2020520804 A JP2020520804 A JP 2020520804A JP 2020537649 A5 JP2020537649 A5 JP 2020537649A5
Authority
JP
Japan
Prior art keywords
seq
sequence
heavy chain
variable region
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020520804A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020537649A (ja
JP7374891B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/055733 external-priority patent/WO2019075417A1/en
Publication of JP2020537649A publication Critical patent/JP2020537649A/ja
Publication of JP2020537649A5 publication Critical patent/JP2020537649A5/ja
Priority to JP2023183034A priority Critical patent/JP2024012366A/ja
Application granted granted Critical
Publication of JP7374891B2 publication Critical patent/JP7374891B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020520804A 2017-10-14 2018-10-12 活性化可能抗cd71抗体による薬物コンジュゲート及びこの使用の方法 Active JP7374891B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023183034A JP2024012366A (ja) 2017-10-14 2023-10-25 活性化可能抗cd71抗体による薬物コンジュゲート及びこの使用の方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762572467P 2017-10-14 2017-10-14
US62/572,467 2017-10-14
PCT/US2018/055733 WO2019075417A1 (en) 2017-10-14 2018-10-12 CONJUGATES OF MEDICAMENT ANTI-CD71 ACTIVATED ANTIBODIES AND METHODS OF USE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023183034A Division JP2024012366A (ja) 2017-10-14 2023-10-25 活性化可能抗cd71抗体による薬物コンジュゲート及びこの使用の方法

Publications (3)

Publication Number Publication Date
JP2020537649A JP2020537649A (ja) 2020-12-24
JP2020537649A5 true JP2020537649A5 (https=) 2021-07-26
JP7374891B2 JP7374891B2 (ja) 2023-11-07

Family

ID=64110112

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020520804A Active JP7374891B2 (ja) 2017-10-14 2018-10-12 活性化可能抗cd71抗体による薬物コンジュゲート及びこの使用の方法
JP2023183034A Pending JP2024012366A (ja) 2017-10-14 2023-10-25 活性化可能抗cd71抗体による薬物コンジュゲート及びこの使用の方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023183034A Pending JP2024012366A (ja) 2017-10-14 2023-10-25 活性化可能抗cd71抗体による薬物コンジュゲート及びこの使用の方法

Country Status (36)

Country Link
US (3) US20190111150A1 (https=)
EP (2) EP3834846A1 (https=)
JP (2) JP7374891B2 (https=)
KR (4) KR102529359B1 (https=)
CN (1) CN111278467B (https=)
AR (1) AR115178A1 (https=)
AU (1) AU2018346969A1 (https=)
BR (1) BR112020007302B1 (https=)
CA (1) CA3077730A1 (https=)
CL (1) CL2020000977A1 (https=)
CO (1) CO2020005685A2 (https=)
CR (1) CR20200206A (https=)
CY (1) CY1123968T1 (https=)
DK (1) DK3691692T3 (https=)
DO (1) DOP2023000150A (https=)
EC (1) ECSP20025198A (https=)
ES (1) ES2864013T3 (https=)
HR (1) HRP20210436T8 (https=)
HU (1) HUE054037T2 (https=)
IL (1) IL273586A (https=)
LT (1) LT3691692T (https=)
MA (1) MA50752B1 (https=)
MD (1) MD3691692T2 (https=)
MX (1) MX2020003723A (https=)
PE (1) PE20210125A1 (https=)
PH (1) PH12020550417A1 (https=)
PL (1) PL3691692T3 (https=)
PT (1) PT3691692T (https=)
RS (1) RS61596B1 (https=)
RU (2) RU2022111211A (https=)
SG (1) SG11202003378WA (https=)
SI (1) SI3691692T1 (https=)
SM (1) SMT202100184T1 (https=)
TW (2) TW202330039A (https=)
UY (1) UY37931A (https=)
WO (1) WO2019075417A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130116404A1 (en) 2011-11-08 2013-05-09 Case Western Reserve University Targeted non-invasive imaging probes of egfr expressing cells
BR112017023862A2 (pt) 2015-05-04 2018-07-17 Cytomx Therapeutics Inc anticorpos anti-cd71, anticorpos anti-cd71 ativáveis, e métodos de uso destes
DK3635009T3 (da) 2017-06-07 2026-03-30 Regeneron Pharma Sammensætninger og fremgangsmåder til internalisering af enzymer
PL3691692T3 (pl) * 2017-10-14 2021-07-19 Abbvie Inc. Koniugaty lek-aktywowalne przeciwciało anty-cd71 i sposoby ich wykorzystania
US12258597B2 (en) 2018-02-07 2025-03-25 Regeneron Pharmaceuticals, Inc. Methods and compositions for therapeutic protein delivery
WO2019183633A1 (en) 2018-03-23 2019-09-26 Case Western Reserve Univeristy Psma targeted conjugate compounds and uses thereof
BR112020023145A2 (pt) 2018-05-17 2021-02-02 Regeneron Pharmaceuticals, Inc. anticorpo anti-cd63 ou fragmento de ligação ao antígeno do mesmo, molécula de ligação ao antígeno biespecífica, proteína terapêutica de múltiplos domínios, polinucleotídeo composição farmacêutica, e, composto
CN121754667A (zh) * 2020-04-08 2026-03-31 阿里亚达治疗公司 用于血脑屏障递送的组合物和方法
JP2023521384A (ja) * 2020-04-09 2023-05-24 シートムエックス セラピューティクス,インコーポレイテッド 活性化可能抗体を含む組成物
CN116194470B (zh) * 2020-07-23 2025-10-03 达因疗法公司 肌肉靶向复合物及其用途
US20250332265A1 (en) 2021-11-09 2025-10-30 Case Western Reserve University Psma targeted conjugate compounds and uses thereof
CN120659627A (zh) * 2022-07-29 2025-09-16 瑞泽恩制药公司 用于转铁蛋白受体(tfr)介导的脑和肌肉递送的组合物和方法
AU2024299328A1 (en) 2023-07-21 2026-01-22 Marrow Therapeutics, Inc. Hematopoietic cell targeting conjugates and related methods
WO2025133132A1 (en) * 2023-12-20 2025-06-26 Institut National De La Sante Et De La Recherche Medicale Novel anti-tfr1 (cd71) antibodies for cancer treatment

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0279862B1 (en) 1986-08-28 1993-11-03 Teijin Limited Cytocidal antibody complex and process for its preparation
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
DK0752248T3 (da) 1992-11-13 2000-11-13 Idec Pharma Corp Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
AU2006284651C1 (en) 2005-08-31 2013-09-12 The Regents Of The University Of California Cellular libraries of peptide sequences (CLiPS) and methods of using the same
US20090304719A1 (en) 2007-08-22 2009-12-10 Patrick Daugherty Activatable binding polypeptides and methods of identification and use thereof
CN101888856B (zh) * 2007-11-07 2014-08-27 塞尔德克斯医疗公司 结合人树突和上皮细胞205(dec-205)的抗体
RU2636046C2 (ru) 2009-01-12 2017-11-17 Сайтомкс Терапьютикс, Инк Композиции модифицированных антител, способы их получения и применения
AU2010241706B2 (en) * 2009-04-29 2015-07-09 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. ERG monoclonal antibodies
CA2761310C (en) 2009-05-07 2017-02-28 Charles S. Craik Antibodies and methods of use thereof
WO2012104344A1 (en) * 2011-02-01 2012-08-09 Genmab A/S Human antibodies and antibody-drug conjugates against cd74
PL2809683T3 (pl) * 2012-01-31 2019-03-29 Sbi Biotech Co., Ltd. Przeciwciało przeciwko fosfolipazie D4
EP2882844B1 (en) 2012-08-10 2018-10-03 Cytomx Therapeutics Inc. Protease-resistant systems for polypeptide display and methods of making and using thereof
CN103145847B (zh) * 2013-02-05 2014-05-21 浙江大学 一种抗cd20抗体-海兔毒素偶联物及其制备方法和应用
BR112017023862A2 (pt) * 2015-05-04 2018-07-17 Cytomx Therapeutics Inc anticorpos anti-cd71, anticorpos anti-cd71 ativáveis, e métodos de uso destes
CN106237341B (zh) * 2016-07-12 2019-07-30 浙江大学 一种抗体偶联药物及其制备方法和应用
PL3691692T3 (pl) * 2017-10-14 2021-07-19 Abbvie Inc. Koniugaty lek-aktywowalne przeciwciało anty-cd71 i sposoby ich wykorzystania

Similar Documents

Publication Publication Date Title
JP2020537649A5 (https=)
HRP20210436T1 (hr) Konjugati protutijela s lijekom koje može aktivirati protutijelo protiv cd71 i postupci njihove upotrebe
JP2022064924A5 (https=)
JP2020500016A5 (https=)
JP2020506900A5 (https=)
JP2020524661A5 (https=)
RU2588467C3 (ru) Стабильные и растворимые антитела, ингибирующие vegf
MX2025004236A (es) Anticuerpo anti proteina reguladora de se?ales alfa (sirpalfana)
IL259940B2 (en) Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
HRP20241563T1 (hr) Postupak liječenja ili ublažavanja metaboličkih poremećaja primjenom agonista glp-1 receptora konjugiranih na antagoniste želučanog inhibitornog peptidnog receptora (gipr)
JP2019504032A5 (https=)
EP4588940A3 (en) Antibody-drug conjugate comprising antibody against human ror1, and use for the same
RU2015101803A (ru) Перекрестно реактивные антитела к jagged 1/k jagged 2, активируемые антитела к jagged и способы их применения
JP2020500538A5 (https=)
JP2020519643A5 (https=)
PE20140133A1 (es) Nuevas proteinas de union a antigenos
JP2021501579A5 (https=)
JP2015120706A5 (https=)
RU2014146503A (ru) Белки, связывающие антиген - лиганд cd30 человека
RU2011105062A (ru) Нейтрализующие антитела против вируса гриппа а и их использование
PE20071055A1 (es) Anticuerpos anti mn
NZ603972A (en) Anti-fgfr2 antibodies
RU2010116152A (ru) Антитело против рецептора il-6
RU2017104815A (ru) Молекулы со специфичностью в отношении cd79 и cd22
JP2021533159A5 (https=)